EMA recommends Vitrakvi for EU marketing authorisation
The EMA has announced its approval for marketing authorisation in the EU for Vitrakvi (larotrectinib), used to treat solid tumours with a specific gene mutation.
List view / Grid view
The EMA has announced its approval for marketing authorisation in the EU for Vitrakvi (larotrectinib), used to treat solid tumours with a specific gene mutation.
Tiny drug-filled nanocarriers, termed ‘nano-submarines’, are being developed to boost the targeted treatment of headaches and tumours, without damaging healthy tissue...